- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intellia Therapeutics Inc (NTLA)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.46
15.28
52 wk Range
6.80
28.25
NTLA Income Statement
Explore the detailed Intellia Therapeutics Inc income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Intellia Therapeutics Inc's growth trends and overall financial health.
| Period Ending: | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 33.05 | 52.12 | 36.28 | 57.88 | 67.67 | |||||||||
Total Revenues Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -43.01% | +57.69% | -30.4% | +59.55% | +16.92% | |||||||||
Cost Of Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 229.81 | 419.98 | 435.07 | 406.91 | 324.45 | |||||||||
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -196.75 | -367.86 | -398.79 | -349.04 | -256.78 | |||||||||
Gross Profit Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -112.9% | -86.96% | -8.41% | +12.48% | +26.43% | |||||||||
Gross Profit Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -595.27% | -705.78% | -1,099.36% | -603.07% | -379.46% | |||||||||
Other Operating Expenses, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 71.1 | 90.31 | 116.5 | 185.23 | 184.21 | |||||||||
| |||||||||||||||||||
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.85 | -458.16 | -515.29 | -534.26 | -440.99 | |||||||||
Operating Income Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -96.11% | -71.05% | -12.47% | -3.68% | +17.46% | |||||||||
EBIT Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -810.37% | -879.04% | -1,420.51% | -923.1% | -651.67% | |||||||||
Net Interest Expenses | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.28 | 8.54 | 49.83 | 47.81 | 29.2 | |||||||||
Net Interest Expenses Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -45.45% | +565.78% | +483.38% | -4.06% | -38.93% | |||||||||
Interest Expense, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Interest And Investment Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.28 | 8.54 | 49.83 | 47.81 | 29.2 | |||||||||
Other Non Operating Expenses, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -1.33 | -11.08 | -15.63 | - | - | |||||||||
EBT, Excl. Unusual Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.89 | -460.7 | -481.09 | -486.46 | -411.8 | |||||||||
Gain (Loss) On Sale Of Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Other Unusual Items, Total | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | -13.49 | -0.1 | - | - | |||||||||
EBT, Incl. Unusual Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.89 | -474.19 | -481.19 | -519.02 | -412.69 | |||||||||
EBT, Incl. Unusual Items Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -99.58% | -77.01% | -1.48% | -7.86% | +20.49% | |||||||||
EBT, Incl. Unusual Items Margin | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -810.49% | -909.78% | -1,326.51% | -896.77% | -609.85% | |||||||||
Income Tax Expense | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income to Company | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.89 | -474.19 | -481.19 | -519.02 | -412.69 | |||||||||
Minority Interest | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.89 | -474.19 | -481.19 | -519.02 | -412.69 | |||||||||
Net Income Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -99.58% | -77.01% | -1.48% | -7.86% | +20.49% | |||||||||
Net Income Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -810.49% | -909.78% | -1,326.51% | -896.77% | -609.85% | |||||||||
Preferred Dividend and Other Adjustments | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income to Common Excl. Extra Items | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.89 | -474.19 | -481.19 | -519.02 | -412.69 | |||||||||
Basic EPS - Continuing Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||||||
Basic EPS - Continuing Operations Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -57.61% | -63.03% | +12.01% | +3.14% | +27.48% | |||||||||
Diluted EPS - Continuing Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 | |||||||||
Diluted EPS - Continuing Operations Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -57.61% | -63.03% | +12.01% | +3.14% | +27.48% | |||||||||
Basic Weighted Average Shares Outstanding | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 70.89 | 76.97 | 88.77 | 98.85 | 108.38 | |||||||||
Diluted Weighted Average Shares Outstanding | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 70.89 | 76.97 | 88.77 | 98.85 | 108.38 | |||||||||
Dividend Per Share | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Dividend Per Share Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | - | - | - | - | |||||||||
EBITDA | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -260.96 | -450.59 | -506.32 | -523.98 | -431.22 | |||||||||
EBITDA Growth | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -100.32% | -72.67% | -12.37% | -3.49% | +17.7% | |||||||||
EBITDA Margin % | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -789.52% | -864.51% | -1,395.77% | -905.33% | -637.23% | |||||||||
EBIT | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -267.85 | -458.16 | -515.29 | -534.26 | -440.99 | |||||||||
* In Millions of USD (except for per share items)
FAQ
What was Intellia Therapeutics Inc’s revenue at year end?
At the end of the last reported fiscal year, Intellia Therapeutics Inc (NTLA) recorded total revenue of 67.67 million USD.
How much revenue did Intellia Therapeutics Inc report in the most recent quarter?
In its most recent quarterly earnings report, Intellia Therapeutics Inc posted revenue of 23.02 million USD.
What was Intellia Therapeutics Inc’s net income for the year?
For the full year, Intellia Therapeutics Inc reported net income of -412.69 million USD.
How much net income did Intellia Therapeutics Inc post in the last quarter?
In the most recent quarter, Intellia Therapeutics Inc (NTLA) posted net income of -95.79 million USD.
What was Intellia Therapeutics Inc’s gross profit for the year?
Gross profit for the year was reported at -256.78 million USD.
How much gross profit did Intellia Therapeutics Inc generate last quarter?
Intellia Therapeutics Inc recorded gross profit of -50.61 million USD in its latest quarterly report.
What was Intellia Therapeutics Inc’s annual operating income?
For the full year, Intellia Therapeutics Inc (NTLA) reported operating income of -440.99 million USD.
What was Intellia Therapeutics Inc’s operating income last quarter?
Quarterly operating income was -98.71 million USD.
What was Intellia Therapeutics Inc’s quarterly EBITDA?
In the latest quarter, EBITDA was reported at -96.33 million USD.
What was the quarter-over-quarter change in EBITDA for Intellia Therapeutics Inc?
EBITDA changed by 11.67% million USD compared to the last quarter.
What is Intellia Therapeutics Inc’s most recent gross profit margin?
The latest reported gross profit margin for Intellia Therapeutics Inc (NTLA) is -219.88% million USD.
What is Intellia Therapeutics Inc’s most recent net income margin?
Net income margin based on recent financials is -416.15% million USD.
What is Intellia Therapeutics Inc’s most recent EBIT margin?
Intellia Therapeutics Inc reported an EBIT margin of -428.86% million USD based on current figures.
How did Intellia Therapeutics Inc’s revenue change compared to the previous quarter?
Revenue changed by 67.01% million USD compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for Intellia Therapeutics Inc?
In the latest quarter, gross profit changed by 22.34% million USD from the previous quarter.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.